Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
1,206people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
cagrilintide-semaglutide (2.4 mg each)
placebo
Lowered body weight from baseline to week 68−10.4
randomisedthe abstract, start to end
… the placebo group (estimated difference, -10.4 percentage points; 95% …
← favours treatmentfavours comparator →
could be chanceMean change in body weight from baseline to week 68cagrilintide-semaglutide (2.4 mg each) vs placebo
−10.4−11.2 to −9.50
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsBody weight & composition
GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated
unlikelylikely
1.001.00 without it
GLP-1 receptor agonists × body weight & compositionhelps?replicated
unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
1 / 6